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Dendritic cells (DCs) are critical regulators of immune
responses. Under noninflammatory conditions,
several human DC subsets have been identified.
Little is known, however, about the human DC
compartment under inflammatory conditions. Here,
we characterize a DC population found in human
inflammatory fluids that displayed a phenotype
distinct from macrophages from the same fluids
and from steady-state lymphoid organ and blood
DCs. Transcriptome analysis showed that they corre-
spond to a distinct DC subset and share gene signa-
tures with in vitro monocyte-derived DCs. Moreover,
human inflammatory DCs, but not inflammatory
macrophages, stimulated autologous memory CD4+
T cells to produce interleukin-17 and induce T helper
17 (Th17) cell differentiation from naive CD4+ T cells
through the selective secretion of Th17 cell-polar-
izing cytokines. We conclude that inflammatory
DCs represent a distinct human DC subset and
propose that they are derived from monocytes and
are involved in the induction and maintenance of
Th17 cell responses.
INTRODUCTION
Numerous studies in mice have shown that dendritic cells (DCs)
are heterogenous and comprise several subtypes with different
phenotypes and functional properties (Heath and Carbone,
2009). In the steady state, committed DC progenitors originating
from the bone marrow give rise to lymphoid organ-resident DCs
and to migratory tissue DCs (Merad and Manz, 2009). During
inflammation appears an additional DC subset, termed ‘‘inflam-336 Immunity 38, 336–348, February 21, 2013 ª2013 Elsevier Inc.matory DCs’’ (infDCs), that differentiates from Ly6Chi monocytes
recruited to the site of inflammation (Leo´n et al., 2007). These
in vivo differentiated monocyte-derived DCs (Mo-DCs) appear
during pathogenic inflammation (Domı´nguez and Ardavı´n,
2010; Greter et al., 2012) and in models of inflammatory
diseases, such as asthma (Hammad et al., 2010) and rheumatoid
arthritis (Campbell et al., 2011). InfDCs can be modeled in vitro
by bone-marrow derived DCs (BM-DC) cultured with GM-CSF
(Xu et al., 2007), although GM-CSF seems dispensable for their
development in vivo (Greter et al., 2012). InfDCs migrate to
lymphoid organs where they can present antigens to both
CD4+ and CD8+ T cells (Ballesteros-Tato et al., 2010; Hammad
et al., 2010; Leo´n et al., 2007) or transfer antigens to resident
DCs (Ersland et al., 2010). In addition, infDCs can activate
memory T cells directly in peripheral tissues (Wakim et al.,
2008). Depending on the inflammatory environment, infDCs
induce T helper 1 (Th1) cell (Leo´n et al., 2007; Nakano et al.,
2009) or Th2 cell-mediated responses (Hammad et al., 2010;
Kool et al., 2008). Many inflammatory environments also trigger
an additional Th cell subtype, Th17 cells, which secrete inter-
leukin-17 (IL-17) and mediate host defense against extracellular
bacteria and fungi. Th17 cell responses during inflammation are
most likely also induced and maintained by DCs, but the precise
type of DCs involved has not been characterized.
In humans, distinct subsets of DCs have also been evidenced.
Blood conventional DCs can be separated into BDCA1+ and
BDCA3+ DCs (Dzionek et al., 2000). Several DC subsets have
been identified in human skin: dermal CD1a+ DCs and CD14+
DCs and epidermal Langerhans cells (Klechevsky et al., 2008).
Although the ontogeny of human DCs remains poorly under-
stood, it is now clear that these DC subsets differ considerably
from the widely used in vitro model of Mo-DCs differentiated in
the presence of GM-CSF and IL-4 (Robbins et al., 2008). An addi-
tional subset of epidermal DCs, termed inflammatory dendritic
epidermal cells (IDECs), has been described in the skin of atopic
dermatitis patients (Wollenberg et al., 1996). These cells express
surface markers different from Langerhans cells and dermal
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are an activated form of skin DCs or represent a distinct subset
that appears only during inflammation. Similarly, a population
of CD11c+ cells observed in the skin of psoriasis patients, but
absent from healthy skin, was proposed to represent a type of
infDCs (Zaba et al., 2009) and to be similar to a population of
blood myeloid cells expressing 6-sulfo LacNAc (slanDC) (Hansel
et al., 2011). These blood cells, however, were recently shown to
be a subset of CD16+monocytes rather than bona fideDCs (Cros
et al., 2010). Therefore, although it has been known for many
years that monocytes have the potential to differentiate into
DCs in vitro (Sallusto and Lanzavecchia, 1994), the in vivo coun-
terpart of human Mo-DCs awaits identification.
In the present study, we have characterized the DCs present in
inflammatory environments in humans. We showed that these
DCs represent a distinct DC subset, most likely derived from
monocytes, that induces Th17 cell differentiation through the
release of Th17 cell-polarizing cytokines.
RESULTS
DCs with a Distinct Phenotype Are Present in Human
Inflammatory Fluids
In order to identify potential infDCs in humans, we analyzed
myeloid cell populations in two different inflammatory environ-
ments: synovial fluid from rheumatoid arthritic patients and
inflammatory tumor ascites from untreated cancer patients. In
both series of samples, we observed the presence of CD11c+
HLA-DR+ cells that could be divided into two main populations:
CD16+BDCA1 cells and CD16BDCA1+ cells (Figures 1A and
1B). BDCA1+ cells from synovial fluid (Figure 1C) and tumor
ascites (Figure 1D) displayed typical DC morphology with
numerous dendrites, distinct from the macrophage-like mor-
phology of CD16+BDCA1– cells (Figures 1C and 1D). BDCA1+
cells represented around 15%of CD11c+ HLA-DR+ cells in syno-
vial fluid (Figure 1E) and 25% in tumor ascites (Figure 1F).
Another defining feature of DCs is their ability to activate
T cells. In an allogeneic mixed leukocyte reaction, BDCA1+ cells
were potent inducers of CD4 T cell proliferation, whereas CD16+
BDCA1 cells were poor stimulators (Figures 1G and 1H).
Constitutive expression of major histocompatibility class II mole-
cules, dendritic morphology, and T cell activation ability there-
fore identify BDCA1+ cells as bona fide DCs. By contrast, CD16+
BDCA1 cells can be defined as macrophages.
A detailed phenotypic analysis showed that these DCs ex-
press CD206, CD11b, and CD172a (Sirpa), similar to CD16+
BDCA1 macrophages (Figure 2A). DCs also express CD14,
although at lower levels thanmacrophages. DCs, but not macro-
phages, express CD1a and FcεRI, whereas neither cell type ex-
pressed CD209 (DC-SIGN). This phenotype was distinct from
that of blood BDCA1+ DCs (Figure 2B). In addition, no population
of CD11c+ HLA-DR+ CD14+ BDCA1+ CD206+ cells could be
found in noninvaded human lymph nodes from untreated breast
cancer patients (Figure 2C), in human tonsils from healthy
patients (data not shown), or in spleens from pancreatic cancer
patients (Figure 2D). Of note, in the spleens of patients with
gastric cancer, which is associated with chronic inflammation
(Grivennikov et al., 2010), we observed CD11c+ HLA-DR+
CD14+ BDCA1+ FcεRI+ CD206+ cells (Figure 2E), indicatingthat this population of DCs can also be found in secondary
lymphoid organs in some inflammatory situations. These results
therefore identify a novel population of DCs present in inflamma-
tory environments. These cells will be referred to as infDCs.
Inflammatory DCs Represent a Distinct DC Subset
To address whether human infDCs correspond to a distinct
subset or to an activated form of conventional DCs, we used
Affymetrix microarrays to compare the transcriptomes of DCs
and macrophages purified from five inflammatory ascites to
that of purified CD14+CD16 and CD14dimCD16+ monocytes
and BDCA1+ DCs from the blood of four healthy donors.
To assess the reliability of the microarray analysis, we com-
pared the expression of messenger RNA (mRNA) encoding
CD14, CD16 and CD1c (BDCA1) across the different populations
analyzed (Figure 3A). We found that mRNA expression of these
markers correlated with the known surface phenotype of the
different populations. Probe sets with a value higher than 25 fluo-
rescence units were selected for analysis. Using a one-way
ANOVA test (with a False Discovery Rate of 0.01), we identified
5,459 genes (corresponding to 5,760 probe sets) that were
differentially expressed among the five populations. We next
selected genes whose expression varied with a minimum fold
change of 2 when compared to the gene expression of infDCs
(n = 2,012) and used them to explore the relationship between
the five cell types examined based on hierarchical clustering
(Figure 3B). This analysis showed that infDCs were more closely
related to inflammatory macrophages than to other populations
(Figure 3C). This finding was further supported by principal
component analysis, which showed in addition that the gene
expression pattern of infDCs was closer to both inflammatory
macrophages and blood BDCA1+ DCs than to monocytes (Fig-
ure 3D). We conclude that infDCs represent a distinct DC
subtype.
Inflammatory DCs Share Molecular Features with Both
Conventional DCs and Inflammatory Macrophages
Focusing on the major functions of DCs, we selected differen-
tially expressed genes corresponding to the biological functions
of antigen processing (GO 0019882), chemotaxis (GO 0006935),
and endocytosis (GO 0006897) (the full list of genes is presented
in Table S1 available online). Hierarchical clustering using these
sets of genes showed that the antigen processing signature of
infDCs was closely related to that of blood BDCA1+ DCs (Fig-
ure 4A), suggesting that antigen processing and presentation is
a cardinal feature of infDCs. By contrast, the chemotaxis and
endocytosis transcriptomic pathways of infDCs were closer to
that of inflammatory macrophages than to those of other popu-
lations, most likely reflecting the effect of the inflammatory envi-
ronment on the properties of infDCs and macrophages. We also
analyzed the expression of pathogen-recognition receptors
(PRR) by the different populations (Figure 4B). The PRR expres-
sion pattern of infDCs was similar to that of inflammatory macro-
phages and close to that of CD14+ monocytes, suggesting
a specialization in the type of pathogens detected by infDCs as
compared to conventional BDCA1+ DCs.
To gain some insight into the development of infDCs, we
analyzed the expression of transcription factors (Figure 4C)
and growth factor receptors (Figure 4D) involved in myeloidImmunity 38, 336–348, February 21, 2013 ª2013 Elsevier Inc. 337
Figure 1. Identification of Dendritic Cells in Human Inflammatory Fluids
Light density cells from arthritic synovial fluid (A) or tumor ascites (B) were stained with anti-HLA-DR, CD11c, BDCA1, and CD16 antibodies and analyzed by flow
cytometry. One representative experiment out of 4 (A) or 12 (B) is shown. Sorted HLA-DR+ CD11c+ CD16 BDCA1+ and HLA-DR+ CD11c+ CD16+ BDCA1 cells
from arthritic synovial fluid (C) or ascites (D) were analyzed by microscopy after Giemsa/May-Gru¨nwald staining. Scale bar represents 10 mm. One representative
experiment out of 3 (C) or 8 (D) is shown. Percentage of CD16BDCA1+ and CD16+ BDCA1 cells among HLA-DR+ CD11c+ cells from arthritic synovial fluid (E) or
ascites (F). Mean ± SD is shown, n = 4 (E) or n = 20 (F).
(G and H) Different numbers of sorted BDCA1+ or BDCA1 from arthritic synovial fluid or ascites were cultured with CFSE-labeled allogeneic CD4 T cells for
6 days. T cell proliferation was assessed by flow cytometry.
(G) One representative experiment out of 8 (3 for synovial fluid and 5 for ascites).
(H) Number of divided T cells after culture with 6,250 antigen-presenting cells. Symbols represent cells from the same donor (open symbol = synovial fluid, filled
symbol = ascites).
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mRNA encoding IRF8 and BATF3 was not selective among the
five cell populations analyzed. The expression of mRNA encod-
ing EGR1, EGR2, and CSFR1 (all involved in macrophage differ-
entiation in mice) was equally high in infDCs and inflammatory
macrophages, as compared to blood BDCA1+ DCs. By contrast,
the expression of mRNA encoding MAFB (which is also involved
in macrophage differentiation in mice) was high in macrophages
and absent in infDCs. Importantly, the expression of mRNA en-
coding IRF4 and FLT3, which are both involved in DC differenti-
ation in mice, was high in blood BDCA1+ DCs and infDCs and
very low in macrophages and monocytes. Finally, we analyzed
the expression of mRNA encoding ZBTB46, a transcription
factor specific of the conventional DC lineage in both mice and338 Immunity 38, 336–348, February 21, 2013 ª2013 Elsevier Inc.humans that is also expressed in murine Mo-DCs (Meredith
et al., 2012; Satpathy et al., 2012). We found that infDCs and
blood BDCA1+ DCs, but not inflammatory macrophages or
monocytes, expressed mRNA encoding ZBTB46. These results
suggest that the developmental pathway of infDCs has charac-
teristics of both DC and macrophage development.
Inflammatory DCs Are Enriched for Gene Signatures
of Monocyte-Derived DCs
To address whether infDCs are the in vivo equivalents of
Mo-DCs, we designed a two-step strategy. First, we identified
gene signatures for macrophages, BDCA1+ DCs, blood CD16+
or CD14+ monocytes, and in vitro-generated Mo-DCs using
different sets of publicly available human expression data
Figure 2. Dendritic Cells from Inflammatory Fluids Display a Distinct Phenotype
(A) Light density cells from arthritic synovial fluid or ascites were stained with anti-HLA-DR, CD11c, BDCA1, CD16 and CD14, CD206, CD1a, CD11b, FcεRI,
CD172a, CD209, or control isotype antibodies and analyzed by flow cytometry. BDCA1+ cells were gated as HLA-DR+ CD11c+ CD16 BDCA1+ and BDCA1
cells gated as HLA-DR+ CD11c+ CD16+ BDCA1. One representative experiment out of 8 (2 for synovial fluid and 6 for ascites) is shown.
(B) Blood PBMC were stained for HLA-DR, CD11c, CD16, BDCA1, and CD14, CD206, CD1a, CD11b, FcεRI, CD172a, CD209, or control isotype antibodies and
analyzed by flow cytometry. Blood DCs were gated as HLA-DR+ CD11c+ CD16 BDCA1+. Representative results of six independent experiments.
(C) HLA-DR+ CD11c+ lymph node cells were stained for CD14 and BDCA1. Representative results of four independent experiments.
(D and E) HLA-DR+ CD11c+ spleen cells from pancreatic cancer patients (D) or gastric cancer patients (E) were stained for CD14, BDCA1, FcεRI, and CD206.
Representative results of three (D) or two (E) independent experiments.
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the transcriptomes of the five populations that we have isolated
for the expression of these signature genes.
To identify gene signatures (or GeneSets), we analyzed gene
expression data from primary immune cell subsets isolated
from tonsil (tonsil BDCA1+ DCs), lung (alveolar macrophages),
blood analyzed directly ex vivo (CD14+ monocytes, CD16+
monocytes, BDCA1+ DCs, B lymphocytes, CD4 T cells, CD8
T cells, NK cells, neutrophils), or after 30 hr of in vitro culture in
the absence of specific stimuli (resting monocytes, resting B
lymphocytes, resting T cells). We also included data sets from
in vitro-generated cells (peripheral blood mononuclear cell-
derived macrophages, monocyte-derived macrophages, and
Mo-DCs). To establish GeneSets specific for Mo-DCs, macro-
phages, BDCA1+ DCs, blood CD14+ monocytes, and CD16+monocytes, we selected for each of these five cell populations
genes expressed at least 2-fold higher than in all the other cell
types examined (Crozat et al., 2010b) (the list of genes for each
GeneSet can be found in Table S2).
We then tested whether these GeneSets were enriched in
infDCs, inflammatory macrophages, blood CD16+ or CD14+
monocytes, or blood BDCA1+ DCs by performing pairwise com-
parisons using gene set enrichment analysis (GSEA). For each
analysis, the output could be represented as a bar code charac-
terized by two parameters: the normalized enrichment score
(NES) and the false discovery rate statistical q value (for more
details, see Experimental Procedures). As internal controls,
GSEA showed that blood BDCA1+ DCs were more enriched
than infDCs for the BDCA1 DC gene signature, whereas inflam-
matory macrophages were more enriched for the macrophageImmunity 38, 336–348, February 21, 2013 ª2013 Elsevier Inc. 339
Figure 3. Human Inflammatory Dendritic Cells Represent a Distinct Subset
Gene expression profiles of purified blood CD14+CD16 monocytes (CD14), CD14dimCD16+ monocytes (CD16), and BDCA1+ DCs (blDC) from four healthy
donors, and purified inflammatory DCs (infDC) and inflammatory macrophages (infM) from five ascites were analyzed by Affymetrix microarrays.
(A) Expression of mRNA encoding CD14, CD16, and CD1c (BDCA1).
(B) We selected 2,012 genes for analysis based on differential expression and fold change > 2 compared to infDC and clustered on a heat map.
(C) Hierarchical clustering of the different samples using the 2,012 selected genes.
(D) Principal component analysis of differentially expressed genes. Principal component 1 and 2 (PC1 and PC2, respectively) were selected as the axes explaining
most of the data variance.
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cated that infDCs were more enriched for the Mo-DC gene
signature than blood BDCA1+ DCs or inflammatory macro-
phages (Figure 5A, left panels).
In order to obtain a wider view of GeneSet enrichment in the
purified populations, we represented the bar code information
for each pairwise GSEA as a dot whose color corresponded to
the cell in which the gene signature was more represented.
The dot area was proportional to the NES and the color intensity
indicated the q value (a dark, large dot indicated a strong enrich-
ment; Figures 5A and 5B). When compared to the four other cell
types studied, inflammatorymacrophages were always enriched
for themacrophage signature (four red dots highlighted by a rect-340 Immunity 38, 336–348, February 21, 2013 ª2013 Elsevier Inc.angle in the second upper panel; Figure 5B), which was not the
case for other GeneSets (there was always at least one green
dot per column). For instance, inflammatory macrophages
were enriched for the Mo-DC gene signature when compared
to blood CD14+ or CD16+ monocytes, or to BDCA1+ DC, but
not when compared to infDCs. Therefore, the macrophage
signature was the dominant gene signature for inflammatory
macrophages. Similarly, the BDCA1+ DC signature was domi-
nant for blood BDCA1+ DCs, the CD16 monocyte signature
was the dominant gene signature for blood CD16+ monocytes,
and the monocyte signature was the dominant gene signature
for blood CD14+ monocytes (however, this GeneSet only
comprised six genes, so results should be taken with caution)
Figure 4. Human Inflammatory Dendritic Cells Share Transcriptomic Signatures with Both Blood Dendritic Cells and Inflammatory Macro-
phages
(A) Hierarchical clustering using sets of differentially expressed genes corresponding to the Gene Ontology biological functions of antigen processing (53 genes),
chemotaxis (73 genes), or endocytosis (100 genes). Populations analyzed were blood CD14+CD16monocytes (CD14), CD14dimCD16+ monocytes (CD16) and
BDCA1+ DCs (blDC), and inflammatory DCs (infDC) and inflammatory macrophages (infM). See also Table S1.
(B) Heat map representing the relative gene expression of pathogen recognition receptors.
(C) Relative gene expression of selected transcription factors.
(D) Relative gene expression of selected growth factor receptors.
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here are relevant to distinguish the different myeloid populations
analyzed.
In order to clarify the relationship of infDCs to the other purified
populations, a similar analysis was applied (Figure 5B, upper
panel). The Mo-DC signature was the dominant gene signature
for infDCs (Figure 5B, four red dots highlighted by a rectangle
in the upper panel) suggesting that, similar to murine infDCs
andBM-DCs (Xu et al., 2007), human infDCs are the in vivo coun-
terparts of Mo-DCs. infDCs were also enriched for the macro-
phage gene signature (second column of the upper panel, threered dots), which in this case cannot be attributed to the inflam-
matory environment because in vitro-generated macrophages
were included to establish the gene signature and possibly
reflects molecular programs resulting from the differentiation
from monocytes. Finally, infDCs were also enriched for the
BDCA1+ DC gene signature (third column of the upper panel,
three red dots), consistent with our previous conclusions that
infDCs expressedmolecular signatures involved in DC functions.
We conclude that infDCs were more enriched for the Mo-DC
gene signature than all other populations analyzed and therefore
most likely represent the in vivo equivalents of Mo-DCs. TheseImmunity 38, 336–348, February 21, 2013 ª2013 Elsevier Inc. 341
Figure 5. Human Inflammatory Dendritic Cells Are Enriched for Monocyte-Derived Dendritic Cell Gene Signature
GSEA of the gene signature (GeneSet) of Mo-DCs, macrophages (macro), blood and tonsil BDCA1+ DCs (BDCA1), blood CD16+ monocytes (CD16), and blood
CD14+ monocytes (mono) was performed.
(A) GSEA results for pairwise comparisons involving infDCs. The GSEA output is represented as a bar code characterized by two parameters: the normalized
enrichment score (NES) and the false discovery rate statistical value (q).
(B) Dot blot representation of all pairwise GSEA comparisons between infDCs, inflammatory macrophages (macro), blood CD16+ (CD16) or CD14+ (CD14)
monocytes, and blood BDCA1+ DCs (BDCA1). GeneSets comprise different number of genes (n). Dot color corresponds to the font color of the population in
which the GeneSet is enriched. The dot area is proportional to the NES, which varies from 1 (no enrichment) to a maximum of 5 (all genes of the GeneSet are
expressed to higher levels in the same population). The color intensity is indicative of the false-discovery rate statistical q value, which estimates the likelihood that
the enrichment of the GeneSet represents a false-positive finding. See also Table S2.
(C) Hierarchical clustering of gene expression for the Mo-DC GeneSet. Data is shown in Log2 centered to median expression across all samples (i.e., values
around the median are shown in black, values above in yellow, and values below in blue).
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Figure 6. Human Inflammatory Dendritic Cells Induce Th17 Cells
(A) Cells from ascites were analyzed for the expression of CD3, CD4, CD25, and CD45RO. Representative result of five independent experiments.
(B)Purifiedmacrophages (infM)orDCs (infDC) fromasciteswerecultured for 6dayswithautologousascitesmemoryCD4Tcells in thepresenceorabsenceofSEB.
After washing and T cell restimulation, cytokine secretionwasmeasured in the supernatant. Symbols represent results from the samedonor (n = 5).Mean is shown.
(C) Purified DCs from ascites were cultured for 18 hr with autologous ascites’ memory CD4 T cells in the presence of SEB, then fixed, permeabilized, and stained
for IFN-g and IL-17A. Representative result of five independent experiments and percentage of each population among T cells are shown. Symbols represent
results from the same donor (n = 5). Mean is shown.
(D) Purifiedmacrophages or DCs from ascites were cultured for 6 days with allogeneic naive CD4 T cells. Cells were fixed, permeabilized, and stained for GATA-3
and RORgt. Representative result of four independent experiments. (E) Purified macrophages or DCs from arthritic synovial fluid or ascites were cultured for
6 days with allogeneic naive CD4 T cells before washing and T cell restimulation. Cytokine secretion wasmeasured in the supernatant. Symbols represent results
from the same donor (n = 3 for synovial fluid, blue symbols, n = 8 for ascites and n = 6 for blood). Mean is shown.
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are derived from monocytes.
Because the Mo-DC signature was highly enriched in infDCs,
inflammatory macrophages and blood BDCA1+ DCs, we next
evaluated whether the shared sets of genes between these pop-
ulations were similar or distinct. Hierarchical clustering showed
that infDCs express higher number of genes from the Mo-DC
signature than BDCA1+ DCs or macrophages (compare the
amount of yellow in the infDC versus the BDCA1 or the macro-
phage samples; Figure 5C). This analysis also showed that the
genes from the Mo-DC signature shared between infDCs and
blood BDCA1+ DCs were different from the genes shared by
infDCs and inflammatory macrophages, confirming that infDCs
display molecular features of both conventional DCs and inflam-
matory macrophages.
Inflammatory DCs Induce Th17 Cell Differentiation
Ex Vivo
We then analyzed the functional properties of infDCs. Inflamma-
tory Mo-DCs in the mouse have been shown to activate memoryT cells directly in the tissues (Wakim et al., 2008). We therefore
addressed whether infDCs from ascites could activate CD4+
T cells isolated from the same ascites. CD4+ T cells in tumor
ascites were mainly memory T cells, as shown by the expression
of CD45RO and absence of CD25 (Figure 6A). InfDCs, but not
inflammatory macrophages, could stimulate ascites’ memory
CD4+ T cells to produce IL-17A (Figure 6B). When incubated
with a superantigen, Staphylococcus aureus Enterotoxin B
(SEB), both cell types could induce autologous memory CD4+
T cells to produce IFN-g, as well as low amounts of IL-13 and
IL-5 (Figure 6B). Virtually no IL-10 was detected with either cell
population (data not shown). In the presence of SEB, both infDCs
and macrophages activated ascites’ memory CD4+ T cells to
produce IL-17A, but infDCs were significantly more efficient (Fig-
ure 6B). Most IL-17A-secreting T cells did not produce IFN-g,
whereas all IFN-g-secreting T cells also secreted IL-17A (Fig-
ure 6C). These results show that infDCs are potent stimulators
of Th17 cells as compared to inflammatory macrophages.
Because infDCs can also be found in secondary lymphoid
organs (Figure 2E), we then addressed the ability of these cellsImmunity 38, 336–348, February 21, 2013 ª2013 Elsevier Inc. 343
Figure 7. Only Inflammatory Dendritic Cells Secrete Th17 Cell-Polarizing Cytokines
(A) Light density cells from ascites were stained with anti-HLA-DR, CD11c, BDCA1, CD16. and ICOS-L or control isotype antibodies and analyzed by flow
cytometry. infDCs were gated as HLA-DR+ CD11c+ CD16 BDCA1+ and inflammatory macrophages (infM) were gated as HLA-DR+ CD11c+ CD16+ BDCA1.
Representative results of four independent experiments.
(B) Purified DCs from ascites were cultured for 6 days with allogeneic naive CD4 T cells in the presence or absence of blocking antibodies, or isotype
control, before washing and T cell restimulation. Cytokine secretion was measured in the supernatant. Symbols represent results from the same donor (n = 4).
Mean is shown.
(C) Purified macrophages or DCs from ascites or DCs from blood of healthy donors were cultured for 24 hr with or without Pam3Csk4 (Pam3) or dimerized CD40-
Ligand (CD40L). Cytokine secretionwasmeasured in the supernatant. Symbols represent results from the same donor (n = 7 for ascites and n = 6 for blood).Mean
is shown. See also Figure S1.
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induced directly ex vivo by infDCs and inflammatory macro-
phages (Figures 6D and 6E). InfDCs and inflammatory macro-
phages induced naive allogeneic CD4+ T cells to produce very
low amounts of IL-13 and IL-5, and similar amounts of IFN-g (Fig-
ure 6E). Virtually no IL-10was detectedwith either cell population
(data not shown). By contrast, only infDCs induced significant
levels of the Th17 cell cytokine IL-17A. Consistent with this, while
very few CD4+ T cells cultured with inflammatory macrophages
expressed RORgt (Figure 6D), a high proportion of the Th cells
induced by infDCs expressed exclusively RORgt and not
GATA-3, the master regulators of Th17 and Th2 lineages respec-
tively (Ivanov et al., 2006; Zheng and Flavell, 1997) (Figure 6E).
We conclude that infDCs, but not inflammatory macrophages,
are potent inducers of Th17 cell-mediated responses ex vivo.344 Immunity 38, 336–348, February 21, 2013 ª2013 Elsevier Inc.Only Inflammatory DCs Secrete Th17 Cell-Polarizing
Cytokines
Finally, we investigated the molecular mechanisms of this
specialization. Costimulation through the ICOS/ICOS-L axis
has recently been shown to be important for Th17 cell differenti-
ation (Paulos et al., 2010). We found that ICOS-Ligand was ex-
pressed at low amounts by both infDCs and inflammatory
macrophages (Figure 7A) and therefore could not explain their
differential Th17 cell polarization ability.
In humans, IL-6, IL1-b, TGFb, and IL-23 have been proposed
to induce the development of Th17 cells (Acosta-Rodriguez
et al., 2007; Manel et al., 2008; Volpe et al., 2008; Wilson et al.,
2007). In order to address the requirement for these cytokines
in infDC-induced Th17 cell polarization, CD4+ naive T cells
were incubated with allogeneic infDCs in the presence of
Immunity
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the antibodies or an isotype control (Figure 7B). The blocking
antibodies did not affect the differentiation of naive T cells into
Th1 (asmeasured by the secretion of IFN-g) or Th2 (asmeasured
by the secretion of IL-5). By contrast, the secretion of IL-17Awas
severely impaired by the blocking antibodies, as compared to
isotype control.
We then analyzed the cytokines secreted by the different
antigen-presenting cells (Figure 7C). We analyzed the secretion
of IL-12p70 after activation with a cocktail of CD40-ligand and
IFN-g in the presence or absence of Pam3Csk4 (Figure S1).
Only infDCs, but not macrophages, secreted IL-12p70. After
activation by Pam3Csk4, a TLR2/TLR1 ligand, or by CD40-li-
gand to mimic the interaction with T cells, infDCs secreted
levels of IL1-b, IL-6, and TNF-a similar to that of inflammatory
macrophages and higher than those secreted by blood
BDCA1+ DCs, even after stimulation. By contrast, stimulated
infDCs, but no other cell type tested, secreted IL-23 after activa-
tion. We conclude that infDCs induce Th17 cell polarization
through the selective secretion of Th17 cell polarizing cytokines,
notably IL-23.
DISCUSSION
We have identified a population of human DCs present in two
different inflammatory environments, ascites from untreated
ovary and breast cancer patients, and synovial fluid from rheu-
matoid arthritis patients. InfDCs displayed a unique phenotype,
including several distinctive markers absent from conventional
DCs. InfDCs were potent stimulators of Th17 cells as compared
to macrophages.
We propose that infDCs are the human equivalents of murine
monocyte-derived inflammatory DCs. Human and mouse
inflammatory DCs share phenotypic similarities: both DC types
express CD11b (Greter et al., 2012; Leo´n et al., 2007), CD206
(Segura et al., 2009), CD172a (Greter et al., 2012), and FcεRI
(Hammad et al., 2010). A cardinal feature of mouse infDCs is
that they are derived from Ly6Chi monocytes and not from
committed DC progenitors (Guilliams et al., 2009; Leo´n et al.,
2007; Naik et al., 2006). Transcriptome analysis showed that
human infDCs express transcription factors involved in both
DC and macrophage development, suggesting that infDCs
have a specific developmental pathway. In addition, infDCs
were specifically enriched for the Mo-DC gene signature and
are therefore most likely derived from monocytes rather than
from DC precursors. Nevertheless, whether infDCs originate
fromCD14+monocytes, which have been shown to be the equiv-
alents of murine Ly6Chigh monocytes (Cros et al., 2010), or from
CD16+ monocytes, could not be determined by our analysis and
remains open for future investigation (GSEA suggests that
infDCs were more enriched for the CD14+ monocyte gene signa-
ture than for the CD16+ monocyte one, but the former only
included 6 genes limiting the reliability of the results, Figure 5B).
Finally, mouse Mo-DCs express the DC lineage-specific tran-
scription factor Zbtb46 (Satpathy et al., 2012), and CSF1R/
CD115 has recently been shown to be important for mouse infDC
development in vivo (Greter et al., 2012). Both ZBTB46 and
CSFR1 were highly expressed in human infDCs, suggesting
a similar developmental pathway.Two series of studies claimed previously to describe inflam-
matory DCs in the skin of atopic dermatitis (Wollenberg et al.,
1996) and psoriasis (Zaba et al., 2009) patients. Similar to infDCs,
IDECs express HLA-DR, CD11c, BDCA1, CD1a, FcεRI, CD206,
and CD11b (Guttman-Yassky et al., 2007; Wollenberg et al.,
2002). These cells are distinct from Langerhans cells, because
they do not express Langerin and do not display Birbeck gran-
ules (Wollenberg et al., 1996). Even if the transcriptome,
morphology, or ontogeny of IDECs has not been analyzed,
because they appear only in lesional skin, it seems reasonable
to hypothesize that IDECs are actually ‘‘inflammatory’’ DCs.
IDECs, however, were not related to Th17 cell environments,
because the acute phase of atopic dermatitis is initiated by
Th2-type inflammation, whereas the chronic phase of the
disease is dominated by a Th1-type response (Bieber, 2010).
Using in vitro differentiated Mo-DC as a model of IDECs, it has
been proposed that IDECs play a role in initiating Th1 cells differ-
entiation (Novak et al., 2004), although the type of Th responses
induced by naturally-occurring IDECs has not been investigated.
The population of HLA-DR+ CD11c+ cells that appears in
inflammatory skin lesions from psoriasis patients have been
termed ‘‘inflammatory dermal’’ DCs (Zaba et al., 2009). Because
the surface markers studied were different from the defining
phenotypic markers of IDECs, it is difficult to determine whether
these cells are similar to IDECs and infDCs. These ‘‘inflammatory
dermal’’ antigen-presenting cells induce Th1 and some Th17
cell polarization when cultured with allogeneic total T cells
(Zaba et al., 2009). They do not express BDCA1 and were
recently proposed to be similar to slanDC (Hansel et al., 2011),
a population of CD16+ antigen-presenting cells found in the
blood (Scha¨kel et al., 2002). It is not clear, however, whether
these ‘‘inflammatory dermal’’ antigen-presenting cells are actual
DCs or activated monocytes or macrophages. Indeed, morpho-
logical evidence is lacking and these cells share a number of
features with dermal macrophages, including expression of
phenotypicmarkers and inflammatory cytokines (Fuentes-Ducu-
lan et al., 2010; Zaba et al., 2010). In addition, slanDC have been
recently shown to be a subset of CD16+monocytes by transcrip-
tomic and functional analysis (Cros et al., 2010).
Monocytes are generally considered to be very plastic cells.
Mouse monocyte-derived infDCs have been shown to induce
Th1- (Leo´n et al., 2007; Nakano et al., 2009) or Th2-mediated
responses (Hammad et al., 2010; Kool et al., 2008) depending
on the pathology. Moreover, human monocytes can be differen-
tiated in vitro into phenotypically and functionally diverse
Mo-DCs with selective Th cell polarization abilities depending
on the growth factors and cytokines used, suggesting that
Mo-DCs may be polarized differently depending on the environ-
ment (Geissmann et al., 2010). Our results show that in the case
of tumor ascites and rheumatoid arthritis, infDCs induce prefer-
entially Th17 cells. Whether other inflammatory environments
induce other types of Th cell polarization in vivo remains open
for future investigation.
The cytokines directing Th17 cell differentiation have been
extensively studied using in vitro stimulation of CD4+ T cells
with recombinant cytokines. IL-6, IL1-b, TGFb, and IL-23 have
been proposed to be involved in human Th17 cell polarization,
but whether all these cytokines are essential has been controver-
sial (Acosta-Rodriguez et al., 2007; Manel et al., 2008; VolpeImmunity 38, 336–348, February 21, 2013 ª2013 Elsevier Inc. 345
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discovery of naturally-occurring Th17 cell-polarizing DCs to
revisit this issue and we found that blocking IL-6, IL1-b, TGFb,
or IL-23 impaired Th17 cell polarization ex vivo. Our results there-
fore confirm that all these cytokines are required for Th17 cell
differentiation. Recently, two types of human Th17 cells have
been described that are induced by different types of pathogens,
Candida albicans and Staphyloccocus aureus (Zielinski et al.,
2012). Similar to Candida albicans-induced Th17 cells, infDC-
induced Th17 cells secreted IL-17 and IFN-g and their differenti-
ation required IL-1b, showing that this Th17 cell profile is also
induced during sterile inflammation.
Th17 cells have been implicated in the pathogenesis of several
autoimmune or inflammatory diseases, including rheumatoid
arthritis, multiple sclerosis, asthma, inflammatory bowel disease,
and psoriasis (Hu et al., 2011), as well as in tumors (Zou and Res-
tifo, 2010). A large number of studies, both in humans and in
mouse models, have evidenced a pathogenic role for IL-17 in
these diseases, and IL-17 has become a major therapeutic
target. Preclinical studies showed that blocking IL-17 with
neutralizing antibodies suppresses collagen-induced arthritis
(Lubberts et al., 2004) or ameliorates symptoms in experimental
autoimmune encephalomyelitis (Hofstetter et al., 2005). More-
over, treating patients with blocking antibodies against IL-23
has shown promising results in the treatment of psoriasis (Kim-
ball et al., 2008; Krueger et al., 2007) and Crohn’s disease (Sand-
born et al., 2008). Our study shows that infDCs are the main
inducers of Th17 cells in arthritic joints, and possibly in other
inflammatory settings, through the secretion of IL-23. The set
of selective markers for infDCs that we define here should allow




Samples of ovarian or breast tumor ascites from untreated patients were ob-
tained from Hoˆpital de l’Institut Curie (Paris) and samples of synovial fluid were
obtained from Hoˆpital Cochin (Paris) in accordance with Institut Curie and IN-
SERM ethical guidelines. Cells were isolated after centrifugation on a Ficoll
gradient (Lymphoprep,Greiner Bio-One) followed by cell sorting onaFACSAria
instrument (BD Biosciences). Samples of lymph nodes from untreated cancer
patients undergoing diagnostic surgery were obtained fromHoˆpital de l’Institut
Curie (Paris) in accordance with the Institut Curie and INSERM ethical guide-
lines. Only lymph nodes considered healthy (noninvaded) after anatomopatho-
logical examination were included in the study. Lymph node samples were cut
into small fragments, digested with 0.1 mg/mL Liberase TL (Roche) in the pres-
ence of 0.1 mg/mL DNase (Roche) for 20 min before addition of 10 mM EDTA.
Cells were filtered on a 40 mm cell strainer (BD Falcon) and washed. DCs were
enriched by depletion of cells expressing CD3, CD15, CD19, CD56, and
CD235a using antibody-coated magnetic beads and magnetic columns
according to manufacturer’s instructions (Miltenyi). Spleen samples were
obtained from pancreatic or gastric cancer patients undergoing surgery at
Hoˆpital de l’Institut Curie or Hoˆpital Saint-Antoine in accordance with institu-
tional guidelines. Light density cells were obtained by centrifugation on a Ficoll
gradient. For two of the pancreatic cancer patients, splenic DCs were previ-
ously shown to be nonactivated (Nascimbeni et al., 2009). Buffy coats from
healthy donors were obtained from Etablissement Franc¸ais du Sang. PBMC
were prepared by centrifugation on a Ficoll gradient.
Flow Cytometry
See Supplemental Experimental Procedures for the list of antibodies
used. Cells were analyzed on a LSR II (BD Biosciences), FACSVerse (BD346 Immunity 38, 336–348, February 21, 2013 ª2013 Elsevier Inc.Biosciences), or MACSQuant (Miltenyi Biotec) instrument. Data was analyzed
with FlowJo (Tree Star).
Morphological Analysis
Cells were subjected to cytospin and colored with May-Grunwald/Giemsa
staining. Pictures were taken with a CFW-1308C color digital camera (Scion
Corporation) on a Leica DM 4000 B microscope.
MLR
Allogeneic CD4+ T cells were isolated from healthy donors’ PBMC by negative
selection using a CD4+ T cell isolation kit (Miltenyi Biotec). CD4+ T cells were
labeled with 5 mM CFSE and cultured (5 3 104 cells/well) with different
numbers of antigen-presenting cells. After 6 days, T cell proliferation was
assessed by flow cytometry.
Affymetrix Microarray Hybridization
The Affymetrix data has been deposited in GEO (Accession number
GSE40484). See Supplemental Experimental Procedures for cell purification
strategies. RNAwas extracted using the RneasyMicro Kit (QIAGEN) according
to the manufacturer’s protocol. For each condition, 100 ng of polysomal-
bound RNA were employed to synthesize double-stranded cDNA using two
successive reverse-transcription reactions according to the standard Affyme-
trix protocol. Labeled DNA was hybridized on the Affymetrix human Gene
ST1.1, an oligonucleotide 28,000-gene microarray processed on an Affymetrix
GeneTitan device.
Statistical Analysis and Data Mining
Statistical analysis was performed using GeneSpring GX 7.3 (Agilent), R
package EMA, and Matlab softwares. Principal component analysis was
performed as previously described (Volpe et al., 2008). See Supplemental
Experimental Procedures for more details.
Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) was performed as previously described
(Crozat et al., 2010a; Robbins et al., 2008). See Supplemental Experimental
Procedures for more details.
Cytokine Secretion
Cells (2.53 104 cells/well) were incubated during 24 hr in Yssel medium in the
presence or absence of 2 mg/mL Pam3Csk4 (Invivogen), 1 mg/mL dimerized
CD40-ligand (Alexis), 1 mg/mL dimerized CD40-ligand and 1000 IU/mL IFNg
(Miltenyi), or 1 mg/mL dimerized CD40-ligand and 1000 IU/mL IFN-g and
2 mg/mL Pam3Csk4. Supernatants were collected and kept at 20C. Cyto-
kine secretion was assessed by CBA (BD Biosciences) or ELISA (for IL-23,
eBioscience).
T Helper Cell Polarization
Naive CD4+ T cells were isolated from healthy donors’ PBMC by negative
selection followed by cell sorting on a FACSAria instrument (BD Biosciences).
Naive CD4+ T cells were gated as CD4+CD25CD45RA+CD45RO. Ascites
memory CD4+ T cells were isolated from by cell sorting on a FACSAria instru-
ment. Ascites CD4+ T cells were gated as CD11cCD4+CD25CD45RO+.
Antigen-presenting cells (2 3 104 cells/well) were cultured with blood naive
or ascites memory CD4+ T cells (53 104 cells/well) for 6 days in Yssel medium.
For memory T cells, cells were cultured in the presence or absence of
0.5 mg/mL Staphylococcus aureus Enterotoxin B (SEB) (Sigma). In some
experiments with naive CD4+ T cells, cells were cultured in the presence of
2.5 mg/mL anti-TGFb, 2.5 mg/mL anti-IL-1b, 2.5 mg/mL anti-IL-6, 0.5 mg/mL
anti-IL-23, or 2.5 mg/mL control isotype (all from R&D systems). After washing,
cells were incubated with anti-CD3/CD28 beads (Invitrogen) for 24 hr in
X-VIVO 15 serum free medium (Lonza). Supernatants were collected and
kept at 20C. Cytokine secretion was assessed by CBA (BD Biosciences).
For 6 day cultures with naive CD4+ T cells, cells were fixed and permeabilized
with intracellular staining reagents according to manufacturer’s instructions
(eBioscience) and stained with eFluor660 anti-GATA3 and PE anti-RORgt
(eBioscience). For intracellular staining on ascites’ memory CD4+ T cells, cells
were analyzed after 18 hr of culture in the presence of SEB and an additional
3 hr in the presence of brefeldin A (Sigma). Cells were stained with APC-Cy7
Immunity
Human Inflammatory DCs Induce Th17 Differentiationanti-CD3 (BD Biosciences), then fixed with Cytofix/Cytoperm (BD Biosci-
ences) according to manufacturer’s instructions. Cells were stained with
FITC anti-IFNg (IOTest) and PE anti-IL17A (eBioscience).
Statistical Analysis
Wilcoxon matched-paired test or Mann-Whitney test were performed using
Prism (GraphPad Software).
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.immuni.2012.10.018.
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